Roche Acquires Tensha Therapeutics for $535,000,000

  • Feed Type
  • Date
  • Company Name
    Tensha Therapeutics
  • Mailing Address
    55 Cambridge Parkway Cambridge, MA 02142 USA
  • Company Description
    Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Under the terms of the agreement, Tensha’s shareholders will receive an upfront cash payment of $115 million, plus additional contingent payments of up to $420 million based on the achievement of certain predetermined clinical and regulatory milestones.

Trending on Xconomy